GenFleet's GFH375 Plus Cetuximab Placed on China's Proposed Breakthrough Therapy List for KRAS G12D Colorectal Cancer
核心洞察
China's Center for Drug Evaluation (搜索) placed GenFleet Therapeutics (搜索)' GFH375 plus cetuximab on the proposed Breakthrough Therapy Designation list on September 18, 2026.
The combination targets KRAS G12D (搜索)-mutant metastatic colorectal cancer (搜索) in patients who have failed oxaliplatin-, fluoropyrimidine- and irinotecan-based chemotherapy.
The application was submitted on August 13, 2026, and the public comment period on the designation closes on September 24, 2026.
GenFleet Therapeutics (搜索) announced on September 22 that its clinical program combining GFH375 with cetuximab was placed on the proposed Breakthrough Therapy Designation (BTD) list by China's National Medical Products Administration (搜索) Center for Drug Evaluation (搜索) (CDE) on September 18. The proposed designation covers KRAS G12D (搜索)-mutant metastatic colorectal cancer (搜索) in patients who have failed prior oxaliplatin-, fluoropyrimidine- and irinotecan-based chemotherapy.
The company submitted the application on August 13, 2026, and the public comment period on the designation closes on September 24, 2026. GenFleet said it had originally planned to announce the program only after it was formally included on the BTD list, but decided to disclose the regulatory review progress at this stage under relevant provisions of the Hong Kong Listing Rules.
Regulatory Mechanism and Remaining Uncertainty
Breakthrough Therapy Designation is a mechanism established by China's CDE to accelerate development of drugs for serious diseases. Programs that receive the designation can access support including closer communication with regulators and rolling review. GenFleet stated that if the cetuximab combination formally receives the designation, it is expected to accelerate clinical development and regulatory review in China.
The company cautioned that the program still carries the potential risk of not receiving approval following the public comment period. GenFleet added that there is no guarantee GFH375 will ultimately be successfully developed or marketed, and it plans not to issue a separate announcement once the program is formally included on the BTD list.
The KRAS G12D Treatment Gap
KRAS gene mutations are among the most common driver gene alterations in colorectal cancer, with G12D the most prevalent mutation subtype. KRAS mutations have long been regarded as "undruggable" targets, leaving patients with very limited later-line treatment options after failure of first-line standard chemotherapy.
GFH375 is a KRAS G12D (搜索) inhibitor independently developed by GenFleet Therapeutics (搜索). GenFleet was listed in Hong Kong in 2025 and focuses on research and development of tumor immunotherapies and precision medicines.
Disclosure Context
GenFleet said its board noted the recent rise in the share price and wished to inform shareholders and potential investors of the group's latest business developments. After making reasonable inquiries, the board confirmed that, apart from the content disclosed in the announcement, it is unaware of any reasons for the share price increase, nor of any inside information required to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The company said its decision to proactively disclose the regulatory review progress reflects its approach to inside information disclosure obligations under the listing rules.